George Harrison Talbot is Director at Nabriva Therapeutics Plc (NBRV). They have made 5 open-market trades across 1 company since 2017, most recently 2020-07-29.
CIK 0001641640
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $40K since 2018, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NBRV | 65,140 | $92K |
Shares reported on the most recent Form 4, priced at the 2020-07-31 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NBRV | BUY | 2018-07-31 | 2018-08-02 | $2.75 | $40K | +5.9% | -2.7% | -22.4% |
| NBRV | SELL | 2017-06-15 | 2017-06-19 | $93.18 | $16K | +19.4% | +14.7% | -1.4% |
| NBRV | SELL | 2017-05-30 | 2017-06-01 | $101.26 | $21K | +0.8% | +17.2% | +0.4% |
| NBRV | SELL | 2017-05-23 | 2017-05-25 | $100.56 | $33K | -2.9% | +7.5% | -14.0% |
| NBRV | SELL | 2017-05-15 | 2017-05-17 | $51.73 | $21K | +0.1% | -7.8% | -3.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.